Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Inclusion Criteria: To be eligible for this trial, patients must meet all the following eligibility criteria. * Patients must have histologically confirmed metastatic solid tumors with pre-identified molecular profiling in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, either refractory to standard therapy or for which no effective standard therapy that increases survival for at least 3 months is available, or they declined standard of care therapy (the treating physician needs document reasons for a patient to decline standard of care therapy and provide justification for participating this study in the medical record, which will be recorded in eCRF). * Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. * Male or female aged ≥18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Adequate organ functions as defined below: * Absolute neutrophil count (ANC) ≥ 1,500 /μL. * Hemoglobin (Hb) ≥ 8.5 g/dL. * Platelets ≥ 100,000 /μL for nab-paclitaxel or ≥ 75,000 /μL for cyclophosphamide. * Total bilirubin ≤ 1.5 × upper limit of normal (ULN); or total bilirubin \< 3.0 × ULN with direct bilirubin ≤ ULN in patients with well documented Gilbert's Syndrome. * ALT and AST ≤ 2.5 × ULN. * Serum albumin ≥ 3 g/dL. * Urinalysis ≤ 1 proteinuria, or urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol), or 24-h urine protein ≤ 1 g (apply to bevacizumab-based regimens onl…